Last reviewed · How we verify
177Lu-RAD202
At a glance
| Generic name | 177Lu-RAD202 |
|---|---|
| Sponsor | Radiopharm Theranostics, Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- HEAT Trial (HER2 Antibody Therapy With Lutetium-177) (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 177Lu-RAD202 CI brief — competitive landscape report
- 177Lu-RAD202 updates RSS · CI watch RSS
- Radiopharm Theranostics, Ltd portfolio CI